# ZipBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zipbio

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.ziptx.bio
- Total disclosed funding: $4M
- Latest round: Seed (Sep 5, 2024)
- Investors on record: 2

## About

Based in Washington, US, and founded in 2023 by Chief Executive Officer Roee Farber, Chief Technology Officer Ariel J. Ben-Sasson, Chief Scientific Officer Ori Hassin, and Chief Medical Officer Ori Zelichov, operates as a biotechnology platform that develops compact proteins using artificial intelligence. In September 2024, ZipBio raised USD 4 million in seed funding led by NFX, with participation from MoreVC. 

ZipBio leverages a proprietary platform called COMPACT, which is a platform that is designed to compress large biological structures into smaller, more therapeutic molecules, maintaining full functionality while improving delivery. The company focuses on ophthalmology and developing preclinical programs that target unmet medical needs in eye health. In addition, the firm developed an artificial intelligence-based platform for creating gene and protein compression. 

The company plans to use the funding from September 2024 to support its research and development.

## Funding rounds

- Seed, Sep 5, 2024, $4M — MoreVC, NFX

## Investors

- MoreVC (https://capitalatlas.ai/funds/morevc) — Seed
- NFX (https://capitalatlas.ai/funds/nfx) — Seed